Tango Therapeutics (TNGX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Tango Therapeutics

NasdaqGM•Healthcare•Biotechnology

$23.35-0.54(-0.02%)Pre-market

Market Cap

$3.52B

P/S

65.4x

P/B

3.4x

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (8/25).

Profitability14/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueLong cash runwayInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 65.4x5y range 3.7x – 65.4x

Currently above its 17-quarter median.

P/B · 3.4x5y range 0.9x – 7.0x

Currently near its 17-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $3.52B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $53.81M
Q. Revenue: $0
TTM EBITDA: $-136.35M
TTM Op. Income: $-136.35M
Q. Op. Income: $-59.78M
TTM Net Income: $-123.72M
Q. Net Income: $-55.34M
EPS: $-0.37
Shares Out.: $149.88M

$53.81M in TTM revenue grew 121.5% YoY, reaching $0 last quarter. TTM EBITDA of $-136.35M and TTM operating income of $-136.35M show growth is flowing through to the bottom line. However, net income is negative at $123.72M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -5978500000.0%
Net Margin: -5534100000.0%

Op. margin of -5978500000.0% is down 5978498712.1% YoY — costs are rising relative to revenue. Net margin at -5534100000.0% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 65.4x
P/B Ratio: 3.4x

P/S of 65.4x and P/B of 3.4x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.07B
Cash: $345.56M
Long-Term Debt: N/A
Book Value: $1.02B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-38.87M
TTM Free Cash Flow: $-144.29M
FCF Margin: -268.1%
FCF / Net Income: 1.2

TTM FCF of $-144.29M on $-38.87M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.